254 related articles for article (PubMed ID: 9263355)
1. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
2. [Essential thrombocythemia: therapy with anagrelide].
Mazzucconi MG; Ferrari A; Balduini CL
Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
[No Abstract] [Full Text] [Related]
3. [Anagrelide--new antiplatelet drug].
Robak T; Treliński J; Hołub A
Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
[TBL] [Abstract][Full Text] [Related]
4. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G
Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
[TBL] [Abstract][Full Text] [Related]
5. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
6. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
7. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
8. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
Pescatore SL; Lindley C
Expert Opin Pharmacother; 2000 Mar; 1(3):537-46. PubMed ID: 11249536
[TBL] [Abstract][Full Text] [Related]
10. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
11. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Tomer A
Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
[TBL] [Abstract][Full Text] [Related]
12. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
13. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
14. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Burkhard R; Adam H; Widmer L; Honegger HP
Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
[TBL] [Abstract][Full Text] [Related]
15. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Dingli D; Tefferi A
Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
17. Indications for lowering platelet numbers in essential thrombocythemia.
Barbui T
Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide, a selective thrombocytopenic agent.
Oertel MD
Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
[TBL] [Abstract][Full Text] [Related]
20. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
[Next] [New Search]